[go: up one dir, main page]

AU2001276952A1 - Method of treating the syndrome of coronary heart disease risk factors in humans - Google Patents

Method of treating the syndrome of coronary heart disease risk factors in humans

Info

Publication number
AU2001276952A1
AU2001276952A1 AU2001276952A AU7695201A AU2001276952A1 AU 2001276952 A1 AU2001276952 A1 AU 2001276952A1 AU 2001276952 A AU2001276952 A AU 2001276952A AU 7695201 A AU7695201 A AU 7695201A AU 2001276952 A1 AU2001276952 A1 AU 2001276952A1
Authority
AU
Australia
Prior art keywords
syndrome
humans
treating
heart disease
risk factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276952A
Inventor
Anton H. Clement
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CPD LLC
Original Assignee
CPD LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CPD LLC filed Critical CPD LLC
Publication of AU2001276952A1 publication Critical patent/AU2001276952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001276952A 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans Abandoned AU2001276952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/639,061 2000-08-15
US09/639,061 US6262062B1 (en) 2000-08-15 2000-08-15 Method of treating the syndrome of coronary heart disease risk factors in humans
PCT/US2001/022467 WO2002013801A2 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans

Publications (1)

Publication Number Publication Date
AU2001276952A1 true AU2001276952A1 (en) 2002-02-25

Family

ID=24562565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276952A Abandoned AU2001276952A1 (en) 2000-08-15 2001-07-17 Method of treating the syndrome of coronary heart disease risk factors in humans

Country Status (4)

Country Link
US (1) US6262062B1 (en)
EP (1) EP1357907A2 (en)
AU (1) AU2001276952A1 (en)
WO (1) WO2002013801A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6498702B1 (en) * 1999-02-22 2002-12-24 Hitachi, Ltd. Magnetic head supporting apparatus having thermally insulated read/write IC mounted on arm portions thereof
US6524251B2 (en) 1999-10-05 2003-02-25 Omnisonics Medical Technologies, Inc. Ultrasonic device for tissue ablation and sheath for use therewith
US6551337B1 (en) 1999-10-05 2003-04-22 Omnisonics Medical Technologies, Inc. Ultrasonic medical device operating in a transverse mode
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
US20050096669A1 (en) * 1999-10-05 2005-05-05 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic medical device to treat coronary thrombus bearing lesions
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
JP2005531557A (en) * 2002-05-17 2005-10-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Use of effective compounds as selective opiate receptor modulators
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
DE10259245A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivatives of asimadolin with covalently bound acids
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Phoenix Labs Unlimited Company Effervescent oral opiate dosage form
CN102078310B (en) * 2003-12-31 2013-01-23 奇马实验室公司 Generally linear effervescent oral fentanyl dosage form and methods of administering
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
PT2724722T (en) * 2006-10-20 2017-03-14 Neurendo Pharma Llc Method of restoring the incretin effect
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EA017849B1 (en) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor co-agonists
DK2136801T3 (en) 2007-03-30 2012-12-17 Tioga Pharmaceuticals Inc KAPPA-OPIAT AGONISTS FOR TREATMENT OF DIARY-DOMINANT AND ALTERNATIVE IRRITABLE GAS Syndrome
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
EA020326B9 (en) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Gip-based mixed agonists for treatment of metabolic disorders and obesity
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
PA8830501A1 (en) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
CN102325539A (en) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 Amide based glucagon superfamily peptide prodrugs
CN102459325B (en) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 Gastropin receptor activating glucagon compound
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp CONJUGATES OF GLUCAGON ANTAGONIST AND GIP AGONIST AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN103179976A (en) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
RU2580317C2 (en) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Peptide pro-drugs of amide glucagon superfamily
BR112013015389A2 (en) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp glucagon analog displaying gip receptor activity
PE20140724A1 (en) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEPTOR COAGONISTS
CA2839867A1 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US8859491B2 (en) 2011-11-17 2014-10-14 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
JP6311708B2 (en) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055175A (en) 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4451470A (en) * 1982-07-06 1984-05-29 E. I. Du Pont De Nemours And Company Analgesic, antagonist, and/or anorectic 14-fluoromorphinans
US4511570A (en) 1983-03-28 1985-04-16 Key Pharmaceuticals, Inc. Senile dementia treatment
HU201675B (en) * 1983-08-26 1990-12-28 Ivan Balkanyi Process for producing oral pharmaceutical compositions with unappetizing effect
US4478840A (en) * 1983-10-11 1984-10-23 E. I. Du Pont De Nemours And Company Appetite suppressing compositions and methods
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US5356900A (en) 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4880813A (en) 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US4877791A (en) 1988-11-01 1989-10-31 Baker Cummins Pharmaceuticals, Inc. Method of treatment for interestitial cystitis
US4857533A (en) 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US4994466A (en) 1990-06-14 1991-02-19 Baker Cummins Pharmaceuticals, Inc. Method of treatment for multiple sclerosis
DE4136215A1 (en) * 1991-11-02 1993-05-06 Ferring Arzneimittel Gmbh, 2300 Kiel, De USE OF OPIATE ANTAGONISTS FOR TREATING ENDOGENIC HYPERINSULINAEMIA
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US6026817A (en) 1996-11-14 2000-02-22 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5878750A (en) 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5727570A (en) 1996-11-14 1998-03-17 Clemens; Anton H. Method of treating hyperlipidemia in humans

Also Published As

Publication number Publication date
WO2002013801A2 (en) 2002-02-21
EP1357907A2 (en) 2003-11-05
US6262062B1 (en) 2001-07-17
WO2002013801A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
AU2001276952A1 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2001249881A1 (en) Method of treating the heart
ZA983451B (en) Substituted imidazoles useful in the treatment of inflammatory diseases.
AU8880701A (en) Cardiac arrhythmia treatment methods
AU2002227234A1 (en) Circulation set for temperature-controlled catheter and method of using the same
MXPA03002813A (en) Compounds useful in the treatment of inflammatory diseases.
WO2002049515A8 (en) Non-invasive method for treating postural instability
EP1018965A4 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU2003216524A1 (en) Methods for inducing vascular remodeling and related methods for treating diseased vascular structures
AU2002367023A1 (en) Compositions and methods for treating heart failure
AU2003214725A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
MXPA03002679A (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias.
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
HUP0203152A3 (en) Method and compositions for treating pulmonary diseases
AU6726700A (en) Method of treating 1,1,1,3,3-pentafluoropropane
AU2001275959A1 (en) Method of treating the syndrome of type 2 diabetes in humans
GB9924692D0 (en) Wood treatment
AU2002315139A1 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
HK1031670A (en) Method of treating the syndrome of coronary heart disease risk factors in humans
AU6835500A (en) Tissue substitute and method for the production thereof
AU2002315032A1 (en) Improved method of treating the syndrome of type 2 diabetes in humans